Ftse Mib
33.251,35
-1,07%
DAX
18.233,38
-0,17%
S&P 500
5.433,74
0,23%
NASDAQ
17.667,56
0,34%
Bitcoin
66.860,77
0,16%
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ MaxCyte Inc (MXCT) MaxCyte Inc (MXCT) Notizie

MaxCyte Inc

MXCT
4,95
0,00 (0,00%)
14 Giu 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
13/6/202423:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/6/202423:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/6/202423:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/6/202423:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/6/202423:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/6/202423:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/6/202422:45EDGAR2Form 8-K - Current report
10/6/202423:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/5/202414:05GLOBEMaxCyte to Participate in William Blair 44th Annual Growth..
22/5/202414:05GLOBEMaxCyte Signs Strategic Platform License Agreement with..
07/5/202423:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/5/202422:14EDGAR2Form 8-K - Current report
07/5/202422:05GLOBEMaxCyte Reports First Quarter 2024 Financial Results and..
10/4/202414:05GLOBEMaxCyte to Report First Quarter 2024 Financial Results on..
02/4/202414:05GLOBEMaxCyte Signs Strategic Platform License with Be Biopharma..
12/3/202421:05GLOBEMaxCyte Reports Fourth Quarter and Full Year 2023 Financial..
05/3/202422:15EDGAR2Form 8-K - Current report
04/3/202423:39EDGAR2Form 3 - Initial statement of beneficial ownership of..
04/3/202422:05GLOBEMaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023..
26/2/202422:22EDGAR2Form 144 - Report of proposed sale of securities
14/2/202422:26EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202418:25EDGAR2Form SC 13G - Statement of acquisition of beneficial..
09/2/202414:05GLOBEMaxCyte to Report Fourth Quarter and Full Year 2023..
01/2/202422:25EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
30/1/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/1/202414:05GLOBEMaxCyte and Wugen Sign Strategic Platform License to..
26/1/202422:45EDGAR2Form 8-K - Current report
26/1/202417:49EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
23/1/202414:05GLOBEMaxCyte Signs Strategic Platform License with Imugene to..
08/1/202422:15EDGAR2Form 8-K - Current report
08/1/202422:05GLOBEMaxCyte Announces Preliminary Unaudited Fourth Quarter and..
04/1/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202414:05GLOBEMaxCyte and Lion TCR form Partnership to Support Global..
02/1/202408:00GLOBEMaxCyte Confirms Appointment of Maher Masoud as President,..
28/12/202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/12/202322:30EDGAR2Form 8-K - Current report
11/12/202322:05GLOBEMaxCyte Announces CEO Transition and Updates Revenue..
06/12/202322:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/12/202323:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/11/202322:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/11/202322:32EDGAR2Form 144 - Report of proposed sale of securities
17/11/202322:05EDGAR2Form SC 13G - Statement of acquisition of beneficial..
16/11/202322:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/11/202314:05GLOBEMaxCyte Joins the Alliance for mRNA Medicines (AMM) as a..
08/11/202323:12EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202322:12EDGAR2Form 8-K - Current report
08/11/202322:05GLOBEMaxCyte Reports Third Quarter 2023 Financial Results and..
06/11/202322:05GLOBEMaxCyte to Participate in Two Upcoming Investor Conferences
04/10/202322:14EDGAR2Form 8-K - Current report
04/10/202322:05GLOBEMaxCyte Announces Preliminary Third Quarter 2023 Revenue and..
Apertura: Min: Max:
Chiusura: 4,95

La tua Cronologia

NASDAQ
MXCT
MaxCyte
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network